Clinical diagnostics by Gnothis single-molecule DNA sequencing of patient blood samples

Reference number 2018-01922
Coordinator Gnothis AB
Funding from Vinnova SEK 990 000
Project duration May 2018 - December 2019
Status Ongoing
Venture Innovationsprojekt i företag 2018
Call Innovationsprojekt i företag - våren 2018

Purpose and goal

Gnothis product for analysis of single DNA molecules sequences is installed at a clinical customer and used for diagnostic pruposes and as well as for clinical therapy in the case of already diagnosed cancer. The aim is to detect cancer in the early stages and thereby enable therapy in a very early phase of the disease. The goal is to create a simple, robust and rapid solution for early cancer diagnosis via blood samples, which can be prescribed by both specialized physicians and physicians in general medicine and other specialties.

Expected results and effects

In this project, Gnothis AB, together with leading doctors in oncology, intends to introduce Gnothis DNA sequencing instruments and analysis at hospital clinics for use in the day-to-day activities in cancer screening and cancer therapy. This will be done by first using Gnothis DNA sequencing instruments to characterize two cancers in detail. After such characterization, blind tests are performed with newly collected patient samples. Subsequently, DNA sequencing instruments are introduced at the clinic for routine use in investigations.

Planned approach and implementation

The project contains four different phases as follows: First, an installation of instruments is done, after which a characterization of the two selected caution types is performed. Then a clinical validation takes place where Gnothis DNA analysis is performed in parallel with already established samples and analyzes in patient cases. Finally, Gnothis DNA analysis is introduced as a complementary part of the assessment of cancer in diagnosis, follow-up and therapy.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.